IRVINE, Calif. / Apr 18, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the... Read More

ATLANTA / Apr 07, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families. The findings of this study, which identified a significant discrepancy between participant self-awareness and actual prevalence of heart... Read More

WASHINGTON / Mar 11, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards’ latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower... Read More

IRVINE, Calif. / Feb 23, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations... Read More

IRVINE, Calif. / Feb 06, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency 1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted 1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of... Read More

IRVINE, Calif. / Feb 02, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system... Read More

IRVINE, Calif. / Jan 30, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on... Read More

IRVINE, Calif. / Jan 02, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards... Read More

SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as one-year results from the CLASP IID registry. The studies confirm the clinical and quality-of-life benefits of mitral regurgitation (MR) reduction... Read More

SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization. The outcomes for the first 150 patients of the... Read More

IRVINE, Calif. , Oct. 25, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook Q3 sales grew 12 percent to $1.48 billion ; constant currency 1 sales grew 11 percent Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent Q3 EPS of $0.63 ; adjusted 1 EPS of $0.59 Received CE Mark for EVOQUE, the first... Read More

SAN FRANCISCO , Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years. These data, which represent the longest clinical follow-up for a low surgical risk cohort of transcatheter aortic valve replacement (TAVR) patients, were presented during a late-breaking... Read More

IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR). The EVOQUE system is the world's first transcatheter valve... Read More

IRVINE, Calif. , Oct. 18, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, October 25, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived... Read More

IRVINE, Calif. , Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7 , 2023. Bernard Zovighian, chief executive officer, and Scott B. Ullem , chief financial officer, are scheduled to speak to conference attendees at 11:00 a.m. ET . A live webcast of the presentation will be available to all... Read More

IRVINE, Calif. , July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion ; constant currency 1 sales grew 12 percent All product groups achieved double digit constant currency sales growth in Q2 Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percent Q2 EPS of $0.50... Read More

IRVINE, Calif. , July 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday, July 26, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the... Read More

PARIS , May 17, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. The data were presented in a late-breaking clinical data session at EuroPCR 2023. The study observed 2,405... Read More

LOS ANGELES , May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, which represent the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7... Read More

IRVINE, Calif. , April 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023 . Highlights and Outlook Q1 sales grew 9 percent to $1.46 billion ; constant currency 1 sales grew 13 percent Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent Q1 EPS of $0.56 ; adjusted 1 EPS of $0.62 Repurchased approximately $250 million of Edwards stock... Read More

IRVINE, Calif. , April 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2023 after the market closes on Wednesday, April 26, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on... Read More

NEW ORLEANS , March 6, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data. Together these studies, presented at the American College of Cardiology ACC.23/WCC, add... Read More

IRVINE, Calif. , Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 , 2023. Michael A. Mussallem, chairman and chief executive officer, is scheduled to present at 11:15 a.m. PT . Bernard Zovighian, president and incoming chief executive officer, and Scott Ullem , chief financial officer, will also... Read More

IRVINE, Calif. , Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance 1 today during its annual investor conference. Highlights of today's conference include: Global market opportunity across 4 product groups projected to double to nearly $20 billion by 2028 Reaffirming... Read More

IRVINE, Calif. , Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem , who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023 . At the 2023 annual... Read More

LONDON , Nov. 27, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. The data were presented during the late-breaking trials session at PCR London... Read More